论文部分内容阅读
目的探讨干扰素α_1b联合胸腺肽α_1治疗乙型肝炎肝硬化的临床疗效。方法 90名患者随机分成治疗组(干扰素α_1b+胸腺肽α_1组)和对照组(干扰素α_1b组),均在保肝、护肝及一般对症治疗基础上给予干扰素α_1b治疗,疗程3个月;治疗组加用胸腺肽α_1,疗程3个月。检测肝功能相关指标的变化。结果 3个月后治疗组肝功能指标改善优于对照组(P<0.05),治疗组血清肝纤维化指标下降较对照组明显(P<0.05),乙肝核酸(HBV-DNA)载量阴转率、HBeAg阴转率治疗组明显高于对照组,差异均有统计学意义(P<0.01)。结论经过干扰素α_1b联合胸腺肽α_1的治疗,肝功能指标明显改善。该方法能有效控制病毒复制,改善肝功能,有利于肝细胞的修复、再生,安全性良好。
Objective To investigate the clinical efficacy of interferon α 1 b combined with thymosin α 1 in the treatment of hepatitis B cirrhosis. Methods Ninety patients were randomly divided into treatment group (interferon α 1 b + thymosin α 1 group) and control group (interferon α 1 b group). All patients were given interferon α 1 b on the basis of liver protection, liver protection and general symptomatic treatment for 3 months. Treatment group with thymosin α_1, treatment for 3 months. Detection of liver function related indicators of change. Results After 3 months, the improvement of liver function in the treatment group was better than that in the control group (P <0.05). The serum hepatic fibrosis index in the treatment group was significantly lower than that in the control group (P <0.05) The rate of HBeAg negative conversion rate in the treatment group was significantly higher than that in the control group, the differences were statistically significant (P <0.01). Conclusion Interferon α_1b combined with thymosin α_1 treatment significantly improved liver function. The method can effectively control virus replication, improve liver function, is conducive to the repair and regeneration of hepatocytes, and has good safety.